Assessing the social value of novel regimens for MDR TB

Location

Baltimore, Maryland, US

Dates

07/01/2014 - 06/01/2015

PI

David Dowdy, MD, PhD, ScM

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation that also incorporate considerations of social value, using novel regimens for MDR-TB as a paradigmatic example.

Projects

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for pediatric contacts of MDR TB...

Read More

Modeling the impact of novel TB drug regimens...

We are constructing mathematical models of TB epidemics in Southeast Asia, India, and Vietnam to explore the potential...

Read More

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More